CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

原发性黑色素瘤中 TIL（肿瘤浸润淋巴细胞）与更好预后的相关性

英文原题：Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis.

查看英文原题

Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis.

PubMed 2025/02/08（内容时间） Am J Surg Q2 · IF 2.3（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

黑色素瘤地区：美国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

TIL 对黑色素瘤的生存具有强烈预测作用，在决定某些患者辅助治疗的风险是否大于获益时，可能有助于风险分层。

研究思路结论见上方概要

背景

TIL（肿瘤浸润淋巴细胞）与黑色素瘤生存之间的关系尚不明确。我们开展了一项大型多中心研究，评估TIL与生存之间的关联。

方法

前哨淋巴结工作组数据库查询了1993年至2024年间具有已知TIL和生存数据的病例。TIL以二分法分析，并分层为非活跃、活跃和缺失。临床病理因素与黑色素瘤特异性生存期（MSS）、总生存期（OS）和无复发生存期（RFS）相关。

结果

在4957例患者中，3980例（80.2%）存在TIL。TIL对MSS（p = 0.0033）、OS（p = 0.0053）和RFS（p = 0.0011）具有预后意义。在分层分析中，brisk TIL与MSS、OS和RFS的关联比non-brisk TIL更强（所有p < 0.04）。在前哨淋巴结阳性的患者中，TIL对MSS、OS和RFS具有预后意义（所有p < 0.03）。

展开英文摘要原文
BACKGROUND

The relationship between tumor infiltrating lymphocytes (TIL) and survival in melanoma is poorly understood. We present a large multicenter study assessing the association between TIL and survival.

METHODS

The Sentinel Lymph Node Working Group database was queried from 1993 to 2024 for cases with known TIL and survival data. TIL was analyzed dichotomously and stratified as non-brisk, brisk, and absent. Clinicopathologic factors were correlated with melanoma-specific survival (MSS), overall survival (OS), and recurrence-free survival (RFS).

RESULTS

Among 4957 patients, TIL was present in 3980 (80.2 %) of patients. TIL was prognostic of MSS (p = 0.0033), OS (p = 0.0053), and RFS (p = 0.0011). In the stratified analysis, brisk TIL was more strongly associated with MSS, OS, and RFS than non-brisk TIL (all p < 0.04). Among patients with a positive sentinel lymph node, TIL was prognostic of MSS, OS, and RFS (all p < 0.03).

CONCLUSIONS

TIL is strongly predictive of survival in melanoma and may be useful in risk stratification when deciding whether risks of adjuvant therapy outweigh benefits for certain patients.

论文信息

作者
Morrison SL、Han G、Elenwa F、Leong SP、Kashani-Sabet M、Pockaj B、Kosiorek HE、White RL Jr
第一作者单位
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.United States
通讯作者单位
Division of Surgical Oncology, Oregon Health &amp; Science University, Portland, OR, USA. Electronic address: vettoj@ohsu.edu.United States
文献类型
多中心研究
期刊
American journal of surgery2025 Aug
原文标识
PubMed 39979140　·　DOI 10.1016/j.amjsurg.2025.116243

在 PubMed 查看 → 出版商原文（DOI） 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →